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Abstract The purpose of this study was to determine
whether staining intensity in conjunction with the percent-
age of positive tumor cells should be used as an indicator of
protein expression detected by immunohistochemistry. A
tissue microarray of 1,197 colorectal cancers was immuno-
stained for p53, Her2/neu, epidermal growth factor
receptor (EGFR), adenomatosis polyposis coli (APC), and
β-catenin. Immunoreactivity was described by the percent-
age of positive tumor cells (percent positivity) and by the
staining intensity (weak, moderate, strong). The interobserver
reproducibility of both was evaluated by two pathologists.
The association of T stage, N stage, tumor grade, vascular
invasion, and survival with percent positivity, staining
intensity, and the combination of both was assessed. In
univariate analysis, protein expression assessed by percent
positivity resulted in 11 significant associations between the
proteins and clinico-pathological features. Eight of these 11
were also demonstrated using only the degree of staining
intensity. However, more than half of the associations
identified by percent positivity alone were lost when staining
intensity was also analyzed in combination with the percentage
of positive tumor cells. A scoring method based on percent
positivity, rather than on staining intensity, for p53, Her2/neu,
EGFR, APC, and β-catenin is reproducible and appears to be
sufficient for establishing associations of the selected tumor
markers with most clinico-pathological features.
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Introduction
Diagnosis and research in colorectal cancer (CRC) routinely
relies on the interpretation of protein expression detected by
means of immunohistochemistry (IHC). The lack of stan-
dardized IHC scoring systems has led to a variety of
unvalidated methods used to assess immunoreactivity. Scor-
ing systems for tumor markers in CRC are usually based on a
measure of the proportion of positive tumor cells and are
often combined with a degree of staining intensity [3, 9, 12,
29]. It is recognized that the interpretation of staining
intensity is not only highly subjective but may be affected
by storage time, variation in protocols, and fixation proce-
dures [2, 13]. Despite these concerns, staining intensity has
become an integral component of many IHC scoring methods
for tumor markers in CRC [7, 8, 10, 12, 23, 25–27].
We have recently shown that a descriptive, semiquanti-
tative scoring system for IHC based on the percentage of
immunoreactive tumor cells (percent positivity) provides a
more complete assessment of the predictive and prognostic
value of several tumor markers in CRC when compared to
an evaluation system using “negative/positive” [16–19].
Additionally, we have studied the interobserver variability
of this semiquantitative method among pathologists for
several proteins namely, epidermal growth factor receptor
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(EGFR), vascular endothelial growth factor, p53, Bcl-2, and
apoptotic protease-activating factor 1 (APAF-1), in tumor
biopsies and tissue microarray (TMA) punches and have
shown that it is reproducible [30, 31, 34].
One of the most important advantages of a semiquanti-
tative scoring method is that it allows the investigator to
establish more biologically or clinically relevant cutoff
scores for positivity for the protein and the outcome under
study rather than relying on an often arbitrary threshold
value, such as 10%, to describe a tumor as “positive.” Such
a method to ascertain cutoff scores has been recently
proposed using receiver operating characteristic (ROC)
curve analysis and has been applied, along with several
other tumor markers, to EGFR and APAF-1 [32–34].
The purpose of this study was to determine whether
staining intensity in conjunction with percent positivity
should be used as an indicator of protein expression detected
by IHC. The associations of p53-, Her2/neu-, EGFR-,
adenomatosis polyposis coli (APC)-, and β-catenin-staining
intensity with a range of clinico-pathological features,
notably T stage, N stage, tumor grade, vascular invasion,
and survival, were evaluated in 1,197 mismatch repair
(MMR)-proficient CRC.
Materials and methods
Tissue microarray construction
ATMA of 1,420 unselected, nonconsecutive CRCs was con-
structed [24]. Briefly, formalin-fixed, paraffin-embedded
tissue blocks of CRC resections were obtained. One tissue
cylinder with a diameter of 0.6 mm was punched from
morphologically representative tissue areas of each donor
tissue block and brought into one recipient paraffin block
(3×2.5 cm) using a homemade semiautomated tissue
arrayer. The resulting TMA set comprised three slides.
Clinico-pathological data
The clinico-pathological data for all patients included T
stage (T1, T2, T3, and T4), N stage (N0, N1, and N2),
tumor grade (G1, G2, and G3), vascular invasion (presence
or absence), and survival time [19].
Immunohistochemistry
Four-micrometer sections of TMA blocks were transferred to
an adhesive-coated slide system (Instrumedics, Hackensack,
NJ). Standard indirect immunoperoxidase procedures were
used for IHC (ABC-Elite, Vector Laboratories, Burlingame,
CA). One thousand four hundred and twenty CRCs were
immunostained for mutL homolog (MLH)1 (clone MLH-1;
dilution 1:100; BD Biosciences Pharmingen, San Jose, CA),
MSH2 (clone MSH-2; dilution 1:200; BD Biosciences
Pharmingen, San Jose, CA), and MSH6 (clone 44; dilution
1:400, Transduction Laboratories). After dewaxing and rehy-
dration in deionized H2O, sections were subjected to heat
antigen retrieval in a microwave oven (1,200 W, 15 min) in
0.001 mol/L ethylenediamine tetraacetic acid at pH 8.0 for
MLH1 and MSH2 and in 0.01 mol/L citrate buffer (pH 7.0)
for MSH6. Endogenous peroxidase activity was blocked
using 0.5% H2O2. The sections were incubated with 10%
normal goat serum (Dako Cytomation, Missassauga, Canada)
for 20 min and incubated with a primary antibody at room
temperature (Her2/neu clone PN2A, DAKO, Denmark; p53
clone DO-7, 1:100; DAKO; cloneβ-catenin-1, dilution 1: 200;
Dako Cytomation, APC clone C20, dilution 1:50; Santa
Cruz, CA). Subsequently, sections were incubated with
secondary antibody (K4005, EnVision+ System-HRP
(AEC); Dako Cytomation) for 30 min at room temperature.
For visualization of the antigen, the sections were immersed
in 3-amino-9-ethylcarbazole+substrate-chromogen (K4005,
EnVision+ System-HRP (AEC); Dako Cytomation) for
30 min and counterstained with Gill’s hematoxylin. IHC
for EGFR was performed using an automated stainer
(EGFR clone 3C6, 3 mg/mL; Ventana Medical Systems,
Tucson, USA) according to the manufacturer’s instructions.
TMA slides for each protein were stained on the same day
under identical conditions.
MMR results
The 1,420 CRCs were stratified according to MMR status: (1)
MMR-proficient tumors expressing MLH1, MSH2, and
MSH6, (2) MLH1-negative tumors, and (3) presumed
hereditary nonpolyposis colorectal cancer (HNPCC) cases
demonstrating loss of MSH2 and/orMSH6 at any age or loss
of MLH1 at age less than 55 years [11]. In population-based
studies, the mean age of diagnosis of Lynch syndrome is
around 55 years. By contrast, sporadic high-level micro-
satellite instability (MSI-H; MMR-deficient) CRC is far more
age-related with a mean age of onset of around 75 years and
few cases occurring younger than 60 years. A cutoff of
55 years was set as a reasonable compromise for distinguish-
ing CRCs with loss of MLH1 into likely HNPCC syndrome
vs likely sporadic. These immunohistochemical groupings
showed a good fit with the known clinicopathological
features associated with these subsets of CRC. Particularly,
the MLH1-negative group was associated with advanced
age, predilection for women and the proximal colon, large
tumor size, and poor differentiation. The presumed HNPCC
group was young and showed no gender difference, and
there was a predilection for the proximal colon as compared
with the MMR-proficient group. While it is possible that a
small proportion of presumed sporadic MSI-H and HNPCC
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cases were incorrectly assigned, the overall findings are
likely to be valid in view of the large numbers of samples
and the good fit with clinico-pathological features. Only
MMR-proficient tumors were included in the study to
ensure a homogeneous sample of tumors (N=1,197, 84.4%).
IHC evaluation
Immunoreactivity was evaluated in all 1,420 punches by
one experienced pathologist. TMA punches with insuffi-
cient tissue or tumor for analysis were excluded from the
study. Protein expression was scored in the nucleus for p53
and β-catenin and in the cytoplasm for APC. EGFR and
Her2/neu positivity were scored in both cell membrane and
cytoplasm. Immunoreactivity was assigned a score based
on the proportion of positive tumor cells over total tumor
cells (percent positivity) ranging from 0 to 100%. Staining
intensity was evaluated as 0=negative, 1=weak, 2=moderate,
and 3=strong. If the staining intensity was heterogeneous,
then scoring was based on the greatest degree of intensity.
MLH1, MSH2, and MSH6 were scored in the nucleus as
negative (0%) and as positive (>0%).
Statistical analysis
Interobserver reproducibility of scoring percent positivity
and staining intensity
To determine the interobserver reproducibility of percent
positivity and staining intensity, a minimum of 100 CRC
punches was evaluated by a second pathologist. The
intraclass correlation coefficient (ICC) defined as the ratio
of the between-subject variance over the between-subject+
within-subject variances was used to determine the reliabil-
ity of percent positivity for each protein. The ICC has
previously been used to assess the agreement of IHC scores
[14, 31]. An ICC of 0.7 or greater is considered sufficient to
establish reproducibility [14]. The interobserver agreement
of staining intensity (negative, weak, moderate, and strong)
was determined using the kappa coefficient (κ) [15]. The
overall κ coefficient measures the reliability of categorical
data while taking into account the probability that both
observers achieved the same scores by chance [1]. The
weighted κ may be used as a measure of inter-rater agreement
for ordinal variables and quantifies the relative difference
between them. The greater the difference is between the
scores, the lower the weighted κ. The interpretation of κ is
commonly made as follows: values between 0.81 and 1.0
represent “almost perfect” agreement, 0.61 and 0.80 “sub-
stantial” agreement, 0.41 and 0.60 “moderate” agreement,
0.21 and 0.40 “fair” agreement, and 0 and 0.20 “slight”
agreement [15].
Univariate analysis
Logistic regression analysis was used to determine the
association of percent positivity or staining intensity with
T stage (early=T1+T2/late=T3+T4), N stage (absence [N0]
or presence [>N0] of lymph node involvement), tumor grade
(low=G1+G2/high=G3), and vascular invasion (absence or
presence). Survival analysis was carried out using Cox
proportional hazards regression.
Fig 1 a–l Weak (left), moderate (center), and strong (right) staining
intensity of nuclear p53 (40×; a–c), membranous EGFR (40×; d–f),
cytoplasmic EGFR (40×; g–i), and membranous Her2/neu (40×; j–l).
m–u Weak (left), moderate (center), and strong (right) staining
intensity of cytoplasmic Her2/neu (40×; m–o), cytoplasmic APC
(40×; p–r), and nuclear β-catenin (40×; s–u)
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Multivariate analysis
Staining intensity and percent positivity were entered into a
multivariate logistic regression model for all binary outcomes,
whereas multiple Cox proportional hazards regression was
performed for survival analysis. Adjusted P values for
percent positivity and staining intensity were obtained.
P values less than or equal to 0.05 indicate a significant
association of percent positivity or staining intensity with
the outcome. All analyses were carried out using SAS
version 9.1 (The SAS Institute, Cary, NC).
Results
Interobserver reproducibility of percent positivity
and staining intensity
The reproducibility of scores expressed as percent positivity
was very strong for p53 (ICC=0.91). The ICCs for APC
(ICC=0.85), β-catenin (ICC=0.78), and membranous
Her2/neu (ICC=0.71) suggest excellent consistency of
scores between observers. The interobserver agreement for
cytoplasmic Her2/neu scores was only slightly lower than
for its membranous counterpart (ICC=0.68). However, the
reliability of membranous and cytoplasmic EGFR expression
was only moderate to low. The same observers independently
re-evaluated EGFR expression a second time by scoring the
number of immunoreactive tumor cells without regard to
localization of staining (i.e., by scoring either membrane and/
or cytoplasmic EGFR). The interobserver agreement was
significantly increased (ICC=0.86) [33].
The agreement of staining intensity between observers
using the overall κ coefficient was only moderate for APC
(κ=0.41) and membranous and cytoplasmic Her2/neu (κ=
0.53 and 0.57, respectively). The reproducibility of staining
intensity for β-catenin was determined to be fair (κ=0.34)
while that of membranous or cytoplasmic EGFR was poor
(κ=0.11 and 0.12, respectively). Analyses with the more
generous weighted κ did little to improve these findings
(Fig. 1; Table 1).
Association of protein expression
with clinico-pathological features
Univariate analysis of percent scores
The evaluation of percent positivity with the clinico-
pathological features identified significant associations
between p53 and T stage (P=0.007) and tumor grade (P=
0.005), membranous EGFR expression and T stage (P=
0.005), N stage (P=0.002), tumor grade (P=0.014), and
survival (P<0.001), and cytoplasmic EGFR expression and
survival (P=0.01). APC expression was correlated with
T stage (P=0.023) and β-catenin expression with tumor
grade (P=0.035), vascular invasion (P=0.008), and survival
(P=0.004). There were no associations of Her2/neu with any
of the clinico-pathological features (Table 2).
Table 1 Interobserver agree-
ment for percent positivity
(percent scores) measured by
the intraclass correlation coef-
ficient (ICC) and for staining
intensity measured by the
overall and weighted kappa
coefficient (κ)
n Nuclear, c cytoplasmic,
m membranous
Protein Measurements of interobserver agreement
Percent scores Staining intensity
ICC Overall κ (95%CI) Weighted κ (95%CI)
p53 (n) 0.91 0.2 (0.11–0.3) 0.5 (0.43–0.57)
APC (c) 0.85 0.41 (0.23–0.58) 0.53 (0.36–0.68)
β-Catenin (n) 0.78 0.34 (0.22–0.47) 0.52 (0.39–0.64)
Her2/neu (m) 0.71 0.53 (0.36–0.69) 0.67 (0.52–0.82)
Her2/neu (c) 0.68 0.57 (0.43–0.71) 0.62 (0.47–0.76)
EGFR (c) 0.54 0.12 (0.0–0.25) 0.26 (0.14–0.39)
EGFR (m) 0.48 0.11 (0.01–0.22) 0.32 (0.22–0.42)
Table 2 Association of protein
expressed as percent positivity
with clinico-pathological fea-
tures by univariate analysis
(P value)
n Nuclear, c cytoplasmic,
m membranous
T stage N stage Tumor grade Vascular invasion Survival
p53 (n) 0.007 0.365 0.005 0.358 0.401
EGFR (m) 0.005 0.002 0.014 0.128 <0.001
EGFR (c) 0.193 0.692 0.382 0.522 0.01
Her2/neu (m) 0.857 0.299 0.551 0.475 0.932
Her2/neu (c) 0.322 0.629 0.235 0.139 0.15
APC (c) 0.023 0.138 0.976 0.205 0.208
β-Catenin (n) 0.619 0.073 0.035 0.008 0.004
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Univariate analysis of staining intensity
All eight significant associations of staining intensity with
the clinico-pathological features were previously established
by percent positivitiy. The associations of membranous
EGFR and tumor grade, β-catenin, vascular invasion, and
survival were not present (Table 3).
Multivariate analysis of percent positivity
and staining intensity
The combined analysis of percent positivity with staining
intensity identified five associations between the proteins
and clinico-pathological features that were previously
found using only the percentage of positive cells. In
addition, the remaining associations found to have statisti-
cal significance in univariate analysis of percent positivity
(p53 with T stage, membranous EGFR with T stage,
N stage, and tumor grade, APC with T stage, and β-catenin
with tumor grade) were no longer observed in combination
with the degree of intensity. In only 1 of the 35 analyses
(2.8%) did staining intensity provide additional information
about the association of the protein with the outcome
(β-catenin with N stage; Table 4).
Discussion
The results of this study confirm that the evaluation of
percent positivity for nuclear p53, cytoplasmic APC,
nuclear β-catenin, and membranous and cytoplasmic
Her2/neu expression is highly reproducible among pathol-
ogists. The assessment of EGFR expression resulted in
strong interobserver agreement when cytoplasmic and/or
membranous immunoreactivity were scored together rather
than in their separate localizations. The intensity of staining
was not reproducible for the proteins in this study.
In the univariate analysis, protein expression assessed as
percent positivity resulted in 11 significant associations
between the proteins and clinico-pathological features.
Eight of these 11 were also demonstrated using only the
degree of staining intensity. However, more than half of the
associations identified by percent positivity alone were lost
when staining intensity was also analyzed.
Scoring systems for tumor markers in CRC are typically
based on some measure of the number of positive tumor cells
and often combined with a degree of staining intensity.
However, Atkins et al. [2] demonstrated using an anti-EGFR
antibody in head and neck cancer, non-small cell lung
carcinomas, and colorectal adenocarcinoma that the degree
Table 4 Association of IHC expressed as percent positivity and clinico-pathological features in multivariate analysis with staining intensity
(adjusted P values)
T stage N stage Tumor grade Vascular invasion Survival
p53 (n) 0.09a 0.643 0.01b 0.745 0.409
EGFR (m) 0.095a 0.19a 0.341a 0.676 0.021b
EGFR (c) 0.777 0.815 0.266 0.339 0.045b
Her2/neu (m) 0.438 0.32 0.46 0.804 0.693
Her2/neu (c) 0.125 0.7 0.327 0.322 0.167
APC (c) 0.137a 0.084 0.815 0.125 0.179
β-catenin (n) 0.446 0.025c 0.062a 0.036b 0.005b
n Nuclear, c cytoplasmic, m membranous
a Loss of significance
b Continued significance
c Gain of significance with the addition of staining intensity
Table 3 Association of stain-
ing intensity with clinico-
pathological features by
univariate analysis (P value)
n Nuclear, c cytoplasmic,
m membranous
T stage N stage Tumor grade Vascular invasion Survival
p53 (n) 0.026 0.127 0.017 0.991 0.61
EGFR (m) 0.005 0.009 0.049 0.192 <0.001
EGFR (c) 0.108 0.447 0.736 0.908 0.017
Her2/neu (m) 0.101 0.51 0.657 0.632 0.738
Her2/neu (c) 0.671 0.487 0.2 0.384 0.364
APC (c) 0.029 0.866 0.714 0.942 0.689
β-catenin (n) 0.424 0.541 <0.001 0.067 0.175
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of staining intensity varied by tumor type, was partially
influenced by the choice of fixatives, and was inversely
correlated with storage time of the unstained tissue sections.
These factors in addition to the variation in IHC protocols
inevitably contribute to the subjective nature of staining
intensity. Contradictory results from different reports on the
same tumor markers may be partially explained by this
subjective assessment of immunoreactivity [23, 26].
We have previously demonstrated that a descriptive,
semiquantitative scoring system based on the percentage of
positive tumor cells (percent positivity) is reproducible and
has several advantages over standard scoring methods based
on predetermined cutoff scores [17–19]. First, this scoring
system allows a more thorough assessment of the predictive
or prognostic significance of tumor markers by evaluating
the entire range of protein expression levels (from 0 to
100%). Moreover, by quantifying protein expression at the
outset, more biologically and clinically relevant cutoff scores
for tumor positivity can be established by, for example,
performing ROC curve analysis [34]. This method has been
used to select cutoff scores for tumor markers macrophage
stimulating factor 1, Raf-1 kinase inhibitor protein, receptor
of hyaluronic acid-mediated motility (RHAMM), APAF-1,
EGFR, as well as for several others involved in trans-
forming growth factor β signaling in CRC [4, 20, 21, 32,
33]. Additionally, the correlations between various proteins
can be assessed. We have recently shown using this scoring
method that the percentage of pERK-positive tumor cells is
strongly associated with increases in RHAMM expression
supporting the hypothesis of a RHAMM–mitogen-activated
protein kinase interaction in MMR-proficient CRC [17]. By
percent scoring, we have also described how classification
and regression tree methods could be used to select proteins
playing a role in predicting rectal tumor response to
preoperative radiotherapy [30]. Finally, this descriptive
scoring method avoids an often complex and interpretative
composite scoring system based on the intensity of staining.
One such method includes a four-tier scoring of the
intensity of staining (0, 1+, 2+, 3+) coupled to either the
mean percentage of positive tumor cells or to a categorical
measure of the percentage of positive tumor cells (for
example, 1–10%, 10–50%, and >50) [3, 6, 9, 12, 29]. A
graded scoring system has also been used where the
percentage of positive tumor cells is categorized (0=no
positivity, 1=1–25%, 2=25–50%, 3=>50%) and multiplied
by the degree of intensity (0, 1, 2, 3) to obtain a score that
is then dichotomized into “low” or “high” expression (low=
score<6 and high=score≥6) [26]. Others have reported only
the degree of staining intensity regardless of the proportion
of immunoreactivity or considered only staining intensities
of 2+ or 3+ as positive for protein expression [24].
The purpose of this study was not to evaluate the
prognostic significance of several tumor markers in CRC
but rather to determine whether staining intensity is a useful
indicator of immunoreactivity in colorectal tumors. In
addition, the study focused on whether staining intensity
provides independent information on the association of the
protein with clinico-pathological features beyond that
which can be obtained from the semiquantitative assess-
ment of immunoreactivity. The markers included in this
study are well established and/or of current interest as
prognostic factors. They were selected to provide a range of
subcellular localizations for scoring purposes (cytoplasm,
cell membrane, nucleus) as well as representing both tumor
suppressors (p53 and APC) and oncogenes (β-catenin,
Her2/neu, and EGFR).
TMA technology allowed us to analyze more than 1,000
CRCs using only three slides. One tissue sample (0.6 mm)
per tumor was obtained. Although it is argued that a single
tissue core may not be representative of the whole tumor,
results using one sample appear to approximate those from
larger tissue sections as more samples are analyzed. In fact,
even larger tissue sections may contain only a small
fraction of the entire tumor mass (1/10,000) [24]. Goethals
et al. [9] reported that four core biopsies are sufficient to
account for tumor heterogeneity. Because the inclusion of
several punches per tumor is not always possible, a larger
series of tumors should compensate for tumor heterogeneity
as was the case in this study. Several studies have shown
well-established associations between molecular features
and clinico-pathological endpoints in TMAs using only one
spot per tumor [5, 22, 28]. Most importantly, evaluating a
single tumor punch may lead to a more reliable analysis of
interobserver agreement for both percent positivity and
staining intensity, as precisely the same area of tumor is
scored by each observer [24].
The results of our study suggest that staining intensity is
not an independent measure of protein expression for the
markers in this study. Additionally, the evaluation of
immunoreactivity using a semiquantitative scoring method
appears to be sufficient for establishing associations of the
selected tumor markers with most clinico-pathological
features.
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